NCT00558662
Completed
Not Applicable
Randomized Controlled Clinical Study to Assess the Clinical Efficacy of the 3M™ Coban™ 2 Layer Compression System Compared to a Short-stretch Compression Bandage in the Treatment of Venous Leg Ulcers
ConditionsVenous Ulcer
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Venous Ulcer
- Sponsor
- Solventum US LLC
- Enrollment
- 234
- Locations
- 16
- Primary Endpoint
- - venous leg ulcer healing
- Status
- Completed
- Last Updated
- last year
Overview
Brief Summary
The study purpose is to compare healing rates, cost effectiveness, quality of life and safety of 12 week compression therapy for the treatment of venous leg ulcers with the 3M™ Coban™ 2 Layer Compression System versus short-stretch compression bandage.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Males or females, age 18 years or older
- •Subjects having a venous leg ulcer (stage C6 according CEAP classification, venous pathology proved by the presence of reflux (Pr)), which is at least 1 cm in any dimension but not larger than 10 cm in any dimension and has at least 5 cm distance to additional ulcers.
- •Subjects who are co-operative, willing to give written informed consent prior to study entry, and willing to comply with the study protocol.
- •Subjects who are able to understand and answer questionnaire items.
- •Subjects who can walk (with or without a walking aid).
- •Subjects who have an ABPI (ankle brachial pressure index) of treated leg greater or equal to 0,8 as measured within four weeks prior to enrollment.
- •Subjects with venous incompetence as defined by reflux longer than 1,0 second in at least one of the following sites: groin \[femoral vein, junction of GSV\], mid thigh medial \[GSV\], hollow of the knee \[popliteal vein, junction of SSV\], mid calf \[SSV\] in the standing position, measured by Doppler, preferably by duplex within the last 12 month without following active treatment of venous reflux.
Exclusion Criteria
- •Subjects with an ABPI \< 0.8 as measured within four weeks prior to enrollment.
- •Subjects whose condition, in the opinion of the investigator, does not require or allow for compression therapy.
- •Subjects where the potential study ulcer is infected, i.e. showing signs of clinical infection (not contamination) as evidenced by purulent, malodorous, or recent increase in drainage and/or peri-wound erythema or elevated temperature.
- •Subjects receiving any systemic antibiotics.
- •Subjects with diagnosed cancerous ulceration.
- •Subjects with diabetic foot ulcers (do not exclude diabetics).
- •Subjects with circumferential wounds.
- •Subjects who started or significantly changed treatment with mood altering substances (e.g. antidepressant drugs) within two weeks prior to enrollment.
- •Subjects who are participating in any prospective clinical study that can potentially interfere with this study.
- •Subjects who are, in the opinion of the clinical investigator, unsuitable for enrollment in this study, for reasons not specified in the exclusion criteria.
Outcomes
Primary Outcomes
- venous leg ulcer healing
Time Frame: 12 weeks
Secondary Outcomes
- - wound size reduction - HRQoL - treatment-cost based on material consumption and visit costs - sub-bandage pressure measurements - AE/SAE(12 weeks)
Study Sites (16)
Loading locations...
Similar Trials
Terminated
Not Applicable
ARISTOCRAT-A Randomized Controlled Trial Evaluating Closure Following Access With the AXERA (Device Name) 2 Access SystemCoronary Artery DiseaseNCT02061696Frank Saltiel39
Terminated
Not Applicable
Clinical Effectiveness of Frozen Thawed Embryo Transfer Compared to Fresh Embryo TransferSubfertilityNCT02570386The University of Hong Kong138
Completed
Phase 3
Randomized Trial to Assess Efficacy and Safety of Continuous Glucose Monitoring in Children 4-<10 Years With T1DMDiabetes Mellitus, Type 1NCT00760526Jaeb Center for Health Research146
Completed
Phase 4
An Efficacy, Safety and Effects on Quality of Life of Tramadol/Paracetamol as Add-on Therapy in Chronic OsteoarthritisOsteoarthritisNCT01728246Janssen Pharmaceutica473
Unknown
Not Applicable
A Feasibility Study of a Novel Phototherapy System for the Management of Acute BurnsBurn WoundNCT04011306Rogers Sciences Inc.15